Cure8 news brief
Delays in diagnosis and restricted access to therapies can allow Crohn’s inflammation to progress, increasing the chance of bowel damage and worse outcomes. Progress on earlier detection and better matching of treatments to patients could reduce harm and improve care.
Adults with Crohn’s disease, caregivers, gastroenterologists and other IBD clinicians, patients on biologic therapies, and researchers working on biomarkers and early-detection studies.
This Healio video/transcript highlights three major challenges in Crohn’s disease care: delayed diagnosis (because symptoms overlap with other GI conditions), limited access to specialty care and therapies (long waits, prior authorizations, insurance-driven step therapy and out-of-pocket costs), and disease heterogeneity that makes it hard to predict which treatment will work best for an individual.
The speaker notes research efforts such as the PROMISE Consortium aimed at earlier detection and risk identification, and emphasizes multidisciplinary care teams (pharmacists, infusion coordinators, nurses) that can help patients navigate insurance and start therapy more quickly.
Practical takeaways are descriptive rather than prescriptive: the piece calls for systemic solutions (more IBD-trained providers, reduced administrative burden) and improved precision-medicine tools rather than offering specific clinical recommendations.
This item is a short Healio video/transcript featuring commentary from an MGH gastroenterologist. It summarizes challenges and priorities rather than presenting new trial data or quantitative findings. PROMISE and other research efforts are mentioned as ongoing work; this is not a report of completed trial results.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Market growth and industry activity can affect drug availability, prices, and the pace of new treatments or diagnostics reaching patients. Increased investment in biomarkers and targeted therapies may lead to better...
This article is a market research summary about the global Crohn’s disease treatment market — it describes sales forecasts, industry players, and market trends rather than new clinical findings or patient-focused...
Patients with IBD may see TREMFYA appearing more widely as a treatment option and influencing which drugs companies prioritize. Rising sales and trial signals can speed access but don’t replace clinical guidance about...
